These results have also been confirmed in breast cancer cell lines and in breast cancer patient-derived xenografts, in which the combination of docetaxel and reparixin was more effective in reducing tumor growth than either treatment alone, with a significant decrease in CSC number through apoptosis by activating Fas/FasL signaling [122] (Table 2). This evidence concerns the gene FAS and breast cancer.